Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its Bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs, and has a focus on single-use technology, or SUT. Its Lab Products and Services division offers a wide range of products for lab use, including scales, pipettes, and filtration equipment. As of 2022, the Bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 74% ownership and 85% voting control. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (37% of 2022 sales), the Americas (37%), and Asia-Pacific (26%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
E: info@sartorius.com
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,528
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,982.40 | 20.70 | 0.26% |
| CAC 40 | 7,329.97 | 5.43 | -0.07% |
| DAX 40 | 21,311.02 | 57.32 | 0.27% |
| Dow JONES (US) | 39,669.39 | 699.57 | -1.73% |
| FTSE 100 | 8,275.60 | 26.48 | 0.32% |
| HKSE | 21,056.98 | 409.29 | -1.91% |
| NASDAQ | 16,307.16 | 516.01 | -3.07% |
| Nikkei 225 | 34,093.78 | 173.38 | 0.51% |
| NZX 50 Index | 12,081.14 | 13.22 | 0.11% |
| S&P 500 | 5,275.70 | 120.93 | -2.24% |
| S&P/ASX 200 | 7,780.20 | 21.30 | 0.27% |
| SSE Composite Index | 3,276.00 | 0.00 | 0.00% |